Abstract
Introduction: We conducted a first-in-human trial evaluating safety and the potential for combined pathogen and circulating tumor cell (CTC) removal in patients with solid metastatic cancers. Methods: The Seraph procedure was performed at a hemodialysis clinic on 10 consecutive patients with metastatic cancer whose liquid biopsy was positive for the epithelial cell adhesion molecule. All the patients exerted positive bacterial or fungal isolates. Results: We have demonstrated the ability of Seraph100® Filter to remove both pathogens and CTCs, with median reduction of 71% within 120 min, from patient blood. Conclusion: High-yield CTC clearance could potentially benefit patients in diagnostic and personalized treatment of cancer to be elucidated in further research.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call